Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
Helen E JoIan GlaspoleChristopher GraingeNicole GohPeter M A HopkinsYuben MoodleyPaul N ReynoldsSally ChapmanE Haydn WaltersChristopher ZappalaHeather AllanGregory J KeirAndrew HayenWendy A CooperAnnabelle M MaharSamantha EllisSacha MacanshTamera J CortePublished in: The European respiratory journal (2017)
7The prevalence of idiopathic pulmonary fibrosis (IPF), a fatal and progressive lung disease, is estimated at 1.25-63 out of 100 000, making large population studies difficult. Recently, the need for large longitudinal registries to study IPF has been recognised.The Australian IPF Registry (AIPFR) is a national registry collating comprehensive longitudinal data of IPF patients across Australia. We explored the characteristics of this IPF cohort and the effect of demographic and physiological parameters and specific management on mortality.Participants in the AIPFR (n=647, mean age 70.9±8.5 years, 67.7% male, median follow up 2 years, range 6 months-4.5 years) displayed a wide range of age, disease severity and co-morbidities that is not present in clinical trial cohorts. The cumulative mortality rate in year one, two, three and four was 5%, 24%, 37% and 44% respectively. Baseline lung function (forced vital capacity, diffusing capacity of the lung for carbon monoxide, composite physiological index) and GAP (gender, age, physiology) stage (hazard ratio 4.64, 95% CI 3.33-6.47, p<0.001) were strong predictors of mortality. Patients receiving anti-fibrotic medications had better survival (hazard ratio 0.56, 95% CI 0.34-0.92, p=0.022) than those not on anti-fibrotic medications, independent of underlying disease severity.The AIPFR provides important insights into the understanding of the natural history and clinical management of IPF.
Keyphrases
- idiopathic pulmonary fibrosis
- lung function
- interstitial lung disease
- clinical trial
- cardiovascular events
- risk factors
- end stage renal disease
- cystic fibrosis
- chronic obstructive pulmonary disease
- multiple sclerosis
- ejection fraction
- newly diagnosed
- air pollution
- cross sectional
- prognostic factors
- randomized controlled trial
- mental health
- quality improvement
- rheumatoid arthritis
- cardiovascular disease
- patient reported outcomes
- case control
- data analysis